Sydney, June 1, 2007 (ABN Newswire) - Pharmaust Limited (ASX: PAA) - Awarded NZ$715k for Specialist GMP Peptide Capabilities - Dr Nick Hagen, CEO of Mimotopes; Boardroomradio is pleased to announce that Pharmaust Limited (ASX: PAA) has published an audio file. The following presentation "Awarded NZ$715k for Specialist GMP Peptide Capabilities" is now available as an instant audio download to your computer. You may also transfer this information to your listening device as an IPod podcast.
The BRR service is based on streaming audio sent in compressed form over the internet and displayed as it arrives. You do not have to wait for the whole file to be downloaded before you can hear it, instead the media is sent in a continuous stream and is played immediately as it reaches your computer. Please note that during live broadcasts there can be a delay of approximately 1-2 minutes, depending on traffic through your Internet Service Provider.
Broadcaster: Pharmaust Limited (ASX: PAA)
Broadcast Title: Awarded NZ$715k for Specialist GMP Peptide Capabilities
Broadcast Type: Audio stream
View the Audio stream for Pharmaust Limited (ASX: PAA) below.
http://www.brr.com.au/event/PAA/1288/23955/wmp/221.242.254.150/?
PodCast Link:
About Pharmaust Limited
PharmAust specialises in the relaunch of existing marketed products for oncology applications making the whole development, regulatory and commercialisation process much faster. In addition, PharmAust's other wholly owned subsidiary, Epichem Pty Ltd generates sales of around $1.7M per annum from contract sales to the pharmaceutical industry of synthetic drugs.
